The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Good afternoon and welcome to HotCopper highlights for Week 4 of the year, I’m Jonathon Davidson. Let’s get into it.

There were lots of quarterlies this week and Liontown drew attention with strong production results. However, lithium prices remain depressed – or depressing – and the company’s former glory has truly re-rated.

Elsewhere, Carnarvon Energy released an update on its Dorado JV project it operates alongside Santos. While the JV says they’re committed to the project, it’s ditched plans to buy an offshore platform and a final investment decision has now been deferred with no firm timeline. That doesn’t sound very committed.

Finally, Clarity Pharmaceuticals made the boards after a second fast track status designation from the US FDA. The company’s copper-based PET scan imaging agent is of interest in the diagnosis of recurrent prostate cancer.

So that was the most viewed – but what about the most discussed?

Botanix remains popular on HotCopper as the company’s anti-sweating drug has brought patient shareholders big returns in the last twelve months.

Kogan generated some chatter with its quarterly on Friday, posting a return to strength.

Finally, Fortescue also made the boards, with its quarterly highlighting record iron ore production.

That’s HotCopper highlights for this week, I’m Jonathon Davidson, have a great weekend and we’ll see you on Monday.

More From The Market Online

Listen: HotCopper Wire Podcast #047 – Maybe just send an email next time, Albo

In this week’s HotCopper Wire episode, Isaac McIntyre and Jonathon Davidson break down (poke holes in) Albo’s national address from 7PM Wednesday, talk
The Market Online Video

Introducing Prairie Lithium: Saskatchewan’s permitted lithium project ready to scale

We've spoken to Prairie Lithium founder Zach Maurer about the explorer's overall mission, right after Macquarie's…
The Market Online Video

US growth, injectable iron pipeline: How AFT Pharma is driving toward $300 million by FY27

AFT Pharmaceuticals (ASX:AFP) is in a red-hot position as we head straight into FY26’s fourth quarter in Australia, and
The Market Online graphic with ASX-branded charts and the text "HotCopper Highlights" centred in white.

HotCopper Highlights, Week 15: Santos, Karoon, Viva all riding the Iran-fuelled Energy rollercoaster

Hello, hello, and welcome to HotCopper Highlights for Week 15, CY26, I’m Isaac McIntyre.